News from the FDA/CDC
News from the FDA/CDC
FDA approves tirzepatide for treating obesity
Zepbound should go to market in the United States by year’s end, with an anticipated monthly list price of $1,060.
News from the FDA/CDC
FDA gives semaglutide two drug safety–related label changes
The second addition concerns a new adverse reaction that was identified during the postmarketing experience: gastrointestinal ileus, an intestinal...
News from the FDA/CDC
FDA panel rejects implanted GLP1-RA dosing device for T2D
“The data show concerning safety signals that need further investigation.”
Latest News
FDA to step up oversight of cosmetics, assess ‘forever chemicals’
The cosmetic products include makeup products, nail polishes, shaving creams, other grooming products, perfumes, face and body cleansers, hair...
News from the FDA/CDC
FDA clears new capabilities for diabetes app BlueStar
The clearance enables the app-based platform to provide bolus insulin dose recommendations that are based on glucose and trend data from a...
News from the FDA/CDC
FDA approves new tubeless insulin pump
It offers users a choice of bolusing directly from the pump or from a handheld remote-control device.
News from the FDA/CDC
FDA okays first-ever new drug for rare bone disorder
The drug reduced annualized heterotopic ossification volume by 54%.
News from the FDA/CDC
FDA approves first over-the-counter birth control pill
The product, OPill, is expected to be available early in 2024.
News from the FDA/CDC
FDA clears the Tandem Mobi insulin pump
The device is approved for people with diabetes aged 6 years and up.
News from the FDA/CDC
FDA OKs empagliflozin for children with type 2 diabetes
This approval represents only the second oral treatment option for children and adolescents with type 2 diabetes after metformin.
News from the FDA/CDC
FDA approves first-ever OTC erectile dysfunction gel
Futura Medical has not announced when it will be available in the United States.